Article

Press Release

Scarinci Will Be Recognized for Dedicated Efforts to Eliminate Cervical Cancer

TogetHER for Health is honoring the contributions of the University of Alabama at Birmingham’s Isabel Scarinci, PhD, with the first-ever Trailblazer Award for her tireless dedication to saving women’s lives both in Alabama and across the world.

Isabel Scarinci, PhD

Isabel Scarinci, PhD

For the first time in history, the world is on a path to permanently end cervical cancer.

TogetHER for Health is honoring the contributions of the University of Alabama at Birmingham’s Isabel Scarinci, PhD, vice chair of Global and Rural Health for the Department of Obstetrics and Gynecology and senior adviser for Globalization and Cancer with the O’Neal Comprehensive Cancer Center, with the first-ever Trailblazer Award for her tireless dedication to saving women’s lives both in Alabama and across the world.

The virtual award ceremony will feature the voices and perspectives of the dedicated health providers, researchers and advocates seeking to permanently remove cervical cancer as a threat to women, their families and communities around the world.

“I am honored to receive this award from such a committed organization that has done so much in the world toward the elimination of cervical cancer as a public health problem, and thrilled that they have partnered with us to wipe out cervical cancer in our home state of Alabama,” Scarinci said.

TogetHER for Health is a global partnership igniting the movement to end cervical cancer everywhere around the world. The mission is to drive awareness, support catalytic programs, and fight for the political and financial resources needed to end this disease.

Related Videos
Kathleen N. Moore, MD, MS
Matthew Powell, MD
Alberto Montero, MD, MBA, CPHQ
Kathleen N. Moore, MD, MS
Amitkumar Mehta, MD
Matthew Powell, MD
Laura J. Chambers, DO
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Aakash Desai, MBBS, MPH